Sagimet Clears FDA Hurdle for Phase 3 Acne Trial
Event summary
- Sagimet received FDA clearance for Phase 3 trial of denifanstat in moderate to severe acne.
- Trial aims to enroll ~800 U.S. patients, with 450 adolescents aged 12–17.
- Denifanstat is an oral once-daily FASN inhibitor with a novel mechanism for acne treatment.
- Phase 3 trial initiation expected in the second half of 2026.
The big picture
Sagimet’s FDA clearance for its Phase 3 trial of denifanstat marks a critical step in addressing moderate to severe acne, a condition affecting ~10 million Americans annually. The trial’s success could validate the company’s FASN inhibitor platform, potentially expanding into other metabolic and fibrotic diseases. With Ascletis’ prior positive results in China, this U.S. trial represents a key test of denifanstat’s global potential.
What we're watching
- Trial Execution
- Whether Sagimet can meet its target enrollment of 800 patients by year-end.
- Regulatory Pathway
- The pace at which denifanstat advances through Phase 3, given prior success in China.
- Market Opportunity
- How denifanstat’s novel mechanism positions it against existing acne treatments.